STOCK TITAN

Cerevel Therapeutics Hldng Inc - CERE STOCK NEWS

Welcome to our dedicated page for Cerevel Therapeutics Hldng news (Ticker: CERE), a resource for investors and traders seeking the latest updates and insights on Cerevel Therapeutics Hldng stock.

Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) is a clinical-stage biopharmaceutical leader pioneering neuroscience therapies for central nervous system disorders. This page serves as the definitive source for official company announcements, research milestones, and financial updates.

Investors and industry observers will find curated press releases covering clinical trial progress, regulatory developments, strategic partnerships, and quarterly results. Our aggregation ensures timely access to material information about CERE's neuropharmacology pipeline targeting Parkinson's, Alzheimer's, and schizophrenia.

All content is verified at source to maintain compliance with financial disclosure standards. Bookmark this page for streamlined tracking of Cerevel's advancements in receptor-specific therapies and neuroscience innovation.

Rhea-AI Summary

AbbVie (NYSE: ABBV) has completed its acquisition of Cerevel Therapeutics (NASDAQ: CERE), strengthening its neuroscience portfolio. The acquisition brings multiple clinical-stage assets, including emraclidine, a potential best-in-class antipsychotic for schizophrenia, and tavapadon, a first-in-class treatment for Parkinson's disease. AbbVie expects the acquisition to be accretive to adjusted diluted EPS beginning in 2030.

The company reaffirms its 2024 full-year adjusted diluted EPS guidance range of $10.71-$10.91, which includes a $0.19 per share dilutive impact from the Cerevel acquisition. AbbVie also maintains its third-quarter adjusted diluted EPS guidance range of $2.92-$2.96. The acquisition is expected to contribute to AbbVie's long-term performance and complement its existing neuroscience pipeline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

BFA LLP has announced an investigation into the merger between Cerevel Therapeutics (NASDAQ: CERE) and AbbVie. Under the merger terms, AbbVie will buy all outstanding shares of Cerevel for $45.00 per share in cash, valuing the company at approximately $8.7 billion. This transaction, approved by the boards of directors of both companies, is set to close in mid-2024. BFA LLP suspects that Cerevel's board was conflicted and agreed to an unfair price for shareholders. Shareholders may have legal options and can obtain more information or legal representation on a contingency fee basis by visiting BFA's website or contacting them directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.59%
Tags
-
Rhea-AI Summary
Cerevel Therapeutics announces positive topline results for tavapadon in a Phase 3 adjunctive trial for people living with Parkinson’s disease. The pivotal TEMPO-3 trial showed a significant increase in 'on' time without dyskinesia compared to placebo. Tavapadon demonstrated potential for motor control, safety, and tolerability. Additional data will be presented at future medical meetings, with Phase 3 monotherapy trial results expected in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.3%
Tags
Rhea-AI Summary
AbbVie Inc. (NYSE: ABBV) is set to acquire Cerevel Therapeutics (NASDAQ: CERE) for a total equity value of approximately $8.7 billion. The acquisition adds a robust neuroscience pipeline to AbbVie's portfolio, focusing on psychiatric and neurological disorders. The transaction is expected to close in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.37%
Tags
-
Rhea-AI Summary
Cerevel Therapeutics (Nasdaq: CERE) to Host Tavapadon Investor Webcast for Phase 3 Development in Parkinson’s Disease Treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
conferences
-
Rhea-AI Summary
Cerevel Therapeutics (Nasdaq: CERE) to participate in two investor conferences in November with President and CEO Ron Renaud joining fireside chats. Live webcasts and archived versions will be available on the company's investor section website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.2%
Tags
conferences
Rhea-AI Summary
Cerevel Therapeutics reported financial results for Q3 2023, raising $499 million from a public offering of common stock. The company's data readout timelines for emraclidine, darigabat, and tavapadon remain on track. Cerevel is well-capitalized with operations supported into 2026. Tavapadon investor webcast scheduled for December 11, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.19%
Tags
-
Rhea-AI Summary
Cerevel Therapeutics to report Q3 2023 financial results and business updates on November 1, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.54%
Tags
conferences earnings
-
Rhea-AI Summary
Cerevel Therapeutics announces pricing of public offering of common stock
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
Rhea-AI Summary
Cerevel Therapeutics announces $400 million public offering of common stock
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
Cerevel Therapeutics Hldng Inc

NYSE:CERE

CERE Rankings

CERE Stock Data

8.19B
76.96M
15.33%
85.12%
3.28%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE